Omicia Acquires Spiral Genetics
Omicia has announced that it has acquired Seattle-based Spiral Genetics. Spiral’s advanced tools add multiple variant detection capabilities for next-generation sequencing (NGS) to Omicia’s software platform.
Spiral’s graph-based technology enables accurate detection of structural variants and provides population-scale data-mining capabilities for clinical laboratories, life science companies and country sequencing programs. Also included in the acquisition are Spiral’s population-specific reference genome and lossless data compression technologies. As a result, Omicia and its customers will have new opportunities to develop novel diagnostics and efficiently manage long-term genomic data storage.
“We’re excited to combine our team and technology with Omicia. Access to Omicia’s diverse customer base, global market position and market-leading platform will help us define the future of healthcare,” said Adina Mangubat, CEO of Spiral Genetics. “Omicia and Spiral have come together to create the most advanced, end-to-end bioinformatics solution in healthcare.”
Omicia now offers a secure, powerful range of NGS analysis capabilities to support high- throughput panels, exomes and whole genomes for identification of hereditary diseases and somatic cancer, delivering clinical reports straight into electronic medical record (EMR) workflows. Omicia’s technology has been used by more than 1,000 research institutions and clinical labs, including population sequencing initiatives (e.g. Genomics England), health systems and hospitals (e.g. University of Pittsburgh Medical Center and Rady Children’s Hospital - San Diego) and national reference laboratories (e.g. LabCorp).
“The strategic integration of Spiral’s technologies effectively cements Omicia’s leadership position in precision medicine. By removing the need to access multiple software platforms, we improves quality, accuracy and turnaround time, removing major roadblocks to clinical adoption,” said Matt Tindall, CEO of Omicia. “Spiral brings a world-class team of commercial leaders, computer scientists and computational biologists with deep expertise in large-scale genome analysis and algorithm development, as well as proven technology and customers.”
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE